a phase i trial investigating a novel oral flt3 inhibitor, bmf-500, in flt3-mutant aml
Published 8 months ago • 138 plays • Length 1:30Download video MP4
Download video MP3
Similar videos
-
2:22
session highlights: idh inhibitors, salvage regimens, and other novel developments in aml
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
1:37
long-term follow-up from a phase ii trial of olutasidenib in idh1-mutated aml
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
2:31
the importance of aml education amongst practitioners
-
5:40
three stages of money laundering
-
2:35
入金管局做mt好難？mt畢業生同你分享入職經過 心路歷程！
-
14:34
aat level 3 business awareness: money laundering
-
1:33
the importance of measurable residual flt3-itd before allosct for aml
-
0:54
idh inhibitors and the evolving aml treatment paradigm
-
0:54
dr. janis abkowitz on the american society of hematology
-
13:40
opening keynote: aml and financial crime risk: how effective are we?
-
1:13
dr. ok-kyong chaekal - hematology and oncology
-
0:48
iam good governance: anti money laundering & corporate criminal offences trailer | e-learning
-
2:23
anti-money laundering
-
0:52
vlad naidzionak, md — hematology/oncology
-
1:35
skillsoft course sample: anti-money laudering (uk)
-
1:11
agent of change - dato' dr khalid abdul kadir, monash medicine & health sciences-malaysia - diabetes
-
1:46
eyad al-hattab, m.d., hematology - mayo clinic health system
-
6:07
all you need to know about 6amld | 6th anti money laundering directive
-
3:30
hematopathology-myeloid-toxic_neutrophils.mp4